Case Presentation. A Case from the Clinic. Additional Data. Examination and Data 10/27/2013
|
|
- Arthur Gordon
- 6 years ago
- Views:
Transcription
1 Northwestern University Feinberg School of Medicine Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus: The Role of New Agents Disclosures: Advisory Board: Incyte Corporation Speaker s Bureau: Incyte Corporation Brady L. Stein, MD MHS Assistant Professor of Medicine Division of Hematology/Oncology and Developmental Therapeutics Institute October 28, 2013 Case Presentation A Case from the Clinic 33 year-old woman with SLE referred after experiencing 7 days of excessive bruising and epistaxis; otherwise asymptomatic SLE since 1998, well controlled, on hydroxychloroquine No fevers, NS, or weight loss; no rash or joint pain New herbal supplement (weight loss product) No other new medications Examination and Data Healthy appearing, no distress Oral mucosal and LE petechiae No lymphadenopathy or splenomegaly Laboratories: WBC: 3.7 x 10 9 /L (mild) Hemoglobin: 11.5 g/dl (mild) Platelets: 2 x 10 9 /L Previously normal Additional Data Negative anti-ds DNA antibody and Normal ESR and CRP Normal anti-phospholipid antibody levels HIV, Hepatitis C and H.pylori negative LDH normal Blood smear notable for severe thrombocytopenia Clinical Diagnosis Acute immune thrombocytopenia, underlying SLE 1
2 Early course Stop herbal supplements *IVIG and Dexamethasone 40mg daily x 4 days Complete response within 7 days ( 146 x 10 9 /L) Rapid decline in platelets, requiring 3 additional courses of pulse Dexamethasone No change in SLE activity (remains quiescent) Steroid-associated long term consequences unacceptable What is the ideal next treatment strategy? Overview: Thrombocytopenia in SLE Epidemiology Differential Diagnosis Pathogenesis Management strategies *Steroids and/or IVIG typical 1 st line approaches to ITP per American Society of Hematology Guidelines (ASH) 2011 Epidemiology: Thrombocytopenia in SLE Definition: Platelets < 100 x 10 9 /L on 2 occasions Prevalence: Complicates course of between 7-30% of SLE patients Precedes official diagnosis of SLE in up to 16% Particularly women with high-titer ANA or other autoantibodies Acute, severe TCP more associated with SLE activity Chronic, moderate TCP less associated with SLE activity Relevance: May associate with increased morbidity, end-organ damage and mortality Diagnostic Evaluation Reviewed by Hepburn, AL et al, Rheumatology 2010 Ziakas, PD Ann Rheum Dis 2005 Zhao Platelets 2010 Thrombocytopenia in SLE: Differential Dx and workup Other Immunemediated processes Evan s syndrome: DAT and hemolysis labs (retic, LDH, etc) TTP: Blood smear, hemolysis labs, ADAMTS 13 testing Macrophage Activation syndrome: Ferritin, triglycerides, LDH Immune thrombocytopenia Anti-plt testing? Anti-phospholipid s? Platelet parameters? (MPV, reticulated plts) Thrombocytopenia in SLE patient Consumption: DIC: D-dimer, PT/PTT fibrinogen Blood loss (NSAIDs/Steroids): Occult stool testing Other vitamin/mineral deficiency: B12 and folate levels Pathogenesis: Immune thrombocytopenia Marrow disorders: MDS/Lymphoma Autoimmune fibrosis: Blood smear/marrow Infection: Typical and atypical Blood and urine cultures, imaging, etc Medication effects: Hold MMF, Azathioprine, MTX, Cyclophosphamide 2
3 Impairments in production and/or survival Impairment in platelet production TPO GP-Ib/IX Increased platelet destruction *GP-IIb/IIIa Management strategies: Older and Newer Splenic clearance Indications and considerations for treatment Age Co-morbidities Cost Lifestyle SLE activity Bleeding history Menorrhagia Platelet count Typical trigger is a platelet count of < x 10 9 /L Need for anticoagulation Anti-phospholipid Antibody Syndrome Platelet goal of 50 or more if requiring anticoagulation or reduced dose of LMWH Need for procedures Older treatments: Splenectomy Splenectomy Decrease in antibody production and platelet clearance Largest series: 25 pts ( ) 88% with immediate response, 64% with sustained responses at 6 yrs Recent series: 20 patients ( ) 85% response rate with lap splenectomy, with disease activity (SLEDAI) scores and decreased steroid dosing -Concerns for poor efficacy and disease activity not confirmed in practice -*Recommended after failure of steroids in primary ITP in eligible candidates Dameshek 1960 Annals of Internal Medicine Hall, et al 1985 Annals of Internal Medicine You, et al 2004 Annals of Surgery *ASH ITP Guidelines 2011 Zhou 2013, Clinical Rheumatology Rituximab: Suppression of antibody production B cell TPO B cells result in polyclonal production, T cell, and dendritic cell activation Anti-CD20 antibody used for B cell depletion in autoimmune and neoplastic diseases Efficacy in Primary ITP Single agent: 40% with platelets > 50 x 10 9 /L at 1 year In Combination: 58-63% response rate with Dexamethasone at 6 months After splenectomy Unlabeled use for primary ITP, optimal dosing unknown, *typically used after failure of steroids/ivig, or splenectomy Godeau Blood 2008 Zaja Blood 2010 Gudbrandsdottir Blood 2013 *ASH ITP Guidelines 2011 Rituximab in SLE-thrombocytopenia Study Design Patients Response rates Jovancevic et al Lupus 2013 Jovancevic et al Lupus 2013 Tew et al Lupus 2010 Terrier et al Art Rheum 2010 Garcia-Carrasco et al Lupus 2010 Case series responders (9 complete) Review of literature Post-hoc analysis from *RCT As reviewed in Jovancevic et al Lupus 2013 *Merrill JT, et al. Art Rheum (10 with TTP) 57 responders (51 complete) Durability 7 long term responders Relapse in 13% 16 Normalized Not reported Prospective 13 evaluable 12 responders (10 complete) Prospective 7 evaluable 6 complete responders Not reported Not reported 3
4 Conclusions: Rituximab in SLE-thrombocytopenia Theoretical rationale given contribution from B cells to SLE/SLE-ITP pathogenesis Efficacy in SLE-ITP likely comparable to that of primary ITP Evidence from smaller, lower quality studies Unclear impact on underlying SLE disease activity Adverse reactions typically infusion-related PML in 2 SLE patients treated with Rituximab Previously on steroids and alkylating agent chemotherapy ACR estimate 2 cases per 8000 patients receiving Rituximab in 2008 Carson, KR et al. Blood 2009 Kavanaugh A, Matteson E Hotline: Rituximab and Progressive Multifocal Leukoencephalopathy. American College of Rheumatology TPO-agonists: Eltrombopag Romiplostim Thrombopoietin Agonists Bussel Lancet 2009; Cheng Lancet 2011 Kuter, Lancet 2008; Kuter, NEJM 2010 Platelet production not maximized in setting of peripheral destruction Insufficient increase in TPO levels Four phase 3 studies support efficacy Romiplostim (SC): Response rates in splenectomized (79%) and nonsplenectomized (88%) patients; lower rates of bleeding, treatment failure, improved quality of life Eltrombopag (PO): Increased (59%) and sustained responses compared to *SOC/placebo; less need for rescue, and allowed for DC other meds *SOC standard of care TPO Agonists Long term therapy usually required Durable response, but platelets decline upon discontinuation Safety concerns/adverse Effects Headache Bone marrow fibrosis Hepatotoxicity (Eltrombopag) Thrombosis, typically in those with additional risk factors? Concern in SLE patients with APLS Portal vein thrombosis in patients with liver disease Saleh, M et al. Blood yr f/u Eltrombopag Kuter, D et al. Br J Haematology year f/u Romiplostim SLE and TPO agonists-limited Evidence Potential Benefit Pregnant SLE patient with Evan s syndrome (plts 3 x 10 9 /L, refractory to steroids, IVIG, Rituxan, Cytoxan Responded to Romisplostim by 3 rd week, induced at 34 weeks 44 yo male SLE/APS patient with Evan s syndrome, developed severe thrombocytopenia (plts 3 x 10 9 /L) Responded to Romiplostim by 4 th week, allowing for splenectomy Alkaabi et al, Lupus 2012 Gonzalez-Nieto, I Lupus 2011 Possible Harm 19 yo with SLE, prior splenic and renal infarct with chronic thrombocytopenia, unresponsive to Rituxan/IVIG, developed renal limited thrombotic microangiopathy (TMA) 6 weeks after Romiplostim 19 yo with APL s and no thrombosis, but severe ITP developed renal TMA after 1 week of Eltrombopag Tomov et al, Lupus 2013 Jansen, et al. NEJM 2011 Other Potential Options Belimumab theoretical rationale, decrease in autoantibody production noted, and fewer hematological flares reported Epratuzumab effect on cytopenias unknown *Azathioprine *Mycophenolate Mofetil *Cyclosporine *Cyclophosphamide Stohl, et al Arthritis and Rheum 2012 Manzi et al Arthritis and Rheum 2010 *These agents can exacerbate thrombocytopenia as well, evidence typically limited Case resolution: Treating Our Patient Age and Co-morbidities Young, no co-morbidities Lifestyle No risky behaviors or occupation SLE activity Quiescent Immunosuppressive therapies not strongly indicated Platelet count Goal at least x 10 9 /L in this case Evidence not strong enough to recommend rituximab over splenectomy Individualized decision making: Splenectomy favored as her most durable option, but have to consider bleeding, infection (early and late), thrombosis Newer therapies not suitable in her case Deferred for now, tolerating prednisone 5mg daily with plts of 60 x 10 9 /L 4
5 Thank you for your attention 5
Evolution of clinical guidelines for ITP: Role of Romiplostim
Slovenian Haematological Society 16 April 2010, Podčetrtek Evolution of clinical guidelines for ITP: Role of Romiplostim Dr. Roberto Stasi Department of Haematology St George's Hospital London Is there
More informationSecond line therapy for ITP should be TPO agonists. Nichola Cooper Imperial Health Care NHS Trust
Second line therapy for ITP should be TPO agonists Nichola Cooper Imperial Health Care NHS Trust COHEM 2012 Antiplatelet antibodies Platelet count after infusion with patient plasma Hours Days T cells
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationDiagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016
Diagnosis and Management of Immune Thrombocytopenias Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016 Disclosures Research support: NIH, CDC, Eisai, Pfizer, Daiichi Sankyo, GlaxoSmithKline,
More informationthrombopoietin receptor agonists and University of Washington January 13, 2012
Tickle me eltrombopag: thrombopoietin receptor agonists and the regulation of platelet production Manoj Menon University of Washington January 13, 2012 Outline Clinical case Pathophysiology of ITP Therapeutic
More informationExpert Review: Updates in Immune Thrombocytopenia. Reference Slides
Expert Review: Updates in Immune Thrombocytopenia Reference Slides Immune Thrombocytopenia (ITP): Overview ITP causality 1,2 Suboptimal platelet production Dysregulated adaptive immune system Increased
More informationDr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune
IMMUNE THROMBOCYTOPENIA Dr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune ITP Megakaryocytes Definition of ITP Primary immune thrombocytopenia Platelet count
More informationThrombocytopenia: a practial approach
Thrombocytopenia: a practial approach Dr. med. Jeroen Goede FMH Innere Medizin, Medizinische Onkologie, Hämatologie FAMH Hämatologie Chefarzt Hämatologie Kantonsspital Winterthur Outline Introduction and
More informationQUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
QUICK REFERENCE 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP) Presented by the American Society of Hematology, adapted from: The American Society of
More informationBleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD
Bleeding Disorders.2 MS4.25.02.2019 Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD Email: abdalla.awidi@gmail.com Case 6: GT 18 yr old female was admitted with pallor, abdominal pain and gum
More informationAcute Immune Thrombocytopenic Purpura (ITP) in Childhood
Acute Immune Thrombocytopenic Purpura (ITP) in Childhood Guideline developed by Robert Saylors, MD, in collaboration with the ANGELS team. Last reviewed by Robert Saylors, MD September 22, 2016. Key Points
More informationWhat is the next step after failure of steroids in ITP? Splenectomy & Rituximab
What is the next step after failure of steroids in ITP? Splenectomy & Rituximab Dr. Roberto Stasi Department of Haematology St George's Hospital and Medical School London Factors that contribute to ITP
More informationIl Rituximab nella ITP
Il Rituximab nella ITP Monica Carpenedo U.O.C Ematologia e TMO, Ospedale San Gerardo, Monza Burning questions about Rituximab and ITP What is the mechanism of action? What is long term effect of treatment?
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationTHE OLD AND THE NEW OF ITP. Alison Street Malaysia April 2010
THE OLD AND THE NEW OF ITP Alison Street Malaysia April 2010 The Harrington-Hollingsworth Experiment Harrington et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru180 Topic: Promacta, eltrombopag Date of Origin: May 8, 2009 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPTANT
More informationContemporary perspectives and initial management of pediatric ITP. William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA
Contemporary perspectives and initial management of pediatric ITP William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA Case Presentation 5 year old female Bruises on trunk, extremities
More informationImmune Thrombocytopenia
Immune Thrombocytopenia David J. Kuter, MD, Dphil Massachusetts General Hospital 2015 Highlights of ASH in Asia Bangkok, Thailand February 28 March 1 Common Causes of Thrombocytopenia Infections Viral
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationAntiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationUpdate on the Management of Immune Thrombocytopenic Purpura (ITP) Dr Raymond Wong Department of Medicine & Therapeutics Prince of Wales Hospital
Update on the Management of Immune Thrombocytopenic Purpura (ITP) Dr Raymond Wong Department of Medicine & Therapeutics Prince of Wales Hospital Immune Thrombocytopenia (ITP) Immune-mediated acquired disease
More informationIdiophatic Thrombocytopenic Purpura: Current Concepts In Pathophysiology And Management
Slovenian Society of Hematology Kranjska Gora, 3-4 October 2008 Idiophatic Thrombocytopenic Purpura: Current Concepts In Pathophysiology And Management Dr. Roberto Stasi S.C. di Oncologia ed Ematologia
More informationImmune Thrombocytopenic Purpura (ITP)
Patient information Immune Thrombocytopenic Purpura Immune Thrombocytopenic Purpura (ITP) This leaflet is for adult patients diagnosed with Immune Thrombocytopenic Purpura also known as Immune Thrombocytopenia
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationPlatelet and WBC disorders
Division of Family Practice Platelet and WBC disorders Adrian Yee MD FRCPC Clinical hematologist Assistant Dean, undergraduate education, IMP asyee@uvic.ca When we understand that slide, we'll have won
More informationPediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY
Pediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY Objectives Review the 2011 American Society of Hematology
More informationRemissions after long term use of romiplostim for immune thrombocytopenia
Published Ahead of Print on September 1, 2016, as doi:10.3324/haematol.2016.151886. Copyright 2016 Ferrata Storti Foundation. Remissions after long term use of romiplostim for immune thrombocytopenia by
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationScottish Medicines Consortium
Scottish Medicines Consortium romiplostim, 250 microgram vial of powder for solution for subcutaneous injection (Nplate ) No. (553/09) Amgen 08 May 2009 (Issued 4 September 2009) The Scottish Medicines
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationHemostatic System - general information
PLATELET DISORDERS Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis Bleeding Diathesis inherited or acquired defects
More informationV.N. KARAZIN KHARKOV NATIONAL UNIVERSITY
V.N. KARAZIN KHARKOV NATIONAL UNIVERSITY Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine Immune thrombocytopenic purpura Abduyeva
More informationUKITP INITAL INFORMATION SHEET (2.4)
UKITP INITAL INFORMATION SHEET (2.4) Barts Health NHS Trust The Royal London Hospital Pathology and Pharmacy Building 80 Newark Street, London E1 2ES Centre for Haematology Institute of and Molecular Science
More informationApproach to thrombocytopenia and management of ITP. Dr.Aby Abraham Dept of Clinical Haematology
Approach to thrombocytopenia and management of ITP Dr.Aby Abraham Dept of Clinical Haematology 04-08-2014 Causes of thrombocytopenia Thrombocytopenia Pseudo True Decreased production Increased destruction
More informationThrombotic Thrombocytopenic
The Treatment of TTP and the Prevention of Relapses GERALD APPEL, MD Professor of Clinical Medicine Columbia University College of Physicians and Surgeons NY-Presbyterian Hospital New York, New York Thrombotic
More informationREVIEW ARTICLE. Immune Thrombocytopenic Purpura ADARSH A K, LAKSHMI KRISHNA INTRODUCTION CLASSIFICATION
ADARSH A K, LAKSHMI KRISHNA REVIEW ARTICLE INTRODUCTION ITP or immune thrombocytopenic purpura is an autoimmune disorder characterized by increased platelet destruction & platelet count < 1 lakh. It is
More informationCorso Nazionale di Aggiornamento in Ematologia Clinica Bolzano giugno 2009
Corso Nazionale di Aggiornamento in Ematologia Clinica Bolzano 18-19 giugno 2009 Nuove prospettive terapeutiche nelle piastrinopenie autoimmuni Marco Ruggeri UO Ematologia, Ospedale San Bortolo, Vicenza
More informationHematology, Transfusion and Cell Therapy
hematol transfus cell ther. 2018;40(1):50 74 Hematology, Transfusion and Cell Therapy www.rbhh.org Special article Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia,
More information5/5/2010. Goldilocks picture from
Sometimes platelet counts are TOO LOW; Goldilocks and the Three Platelets Robert T. Means, Jr., M.D. Professor & Senior Associate Chair Department of Internal Medicine University of Kentucky Lexington
More informationTreatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)
Prescribing Clinical Network Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) Crawley and Horsham & Mid-Sussex CCG Treatment pathway for adult
More informationArthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS
Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients
More informationDR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL
DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL Rare but fatal disease if unrecognized and untreated Incidence about 1: 1 million in the USA Female preponderance of 2:1 Part
More informationMEDICATIONS: THE GOOD, THE BAD, THE UGLY
MEDICATIONS: THE GOOD, THE BAD, THE UGLY July 13, 2013 Dr. Tanaz Kermani Assistant Clinical Professor of Medicine, Division of Rheumatology, David Geffen School of Medicine UCLA Dr. Robert Spiera Professor
More informationRuolo dei nuovi agenti trombopoietici nella terapia dell ITP
42 CONGRESSO NAZIONALE SIE Società Italiana di Ematologia Milano, MIC Centre, 18-21 ottobre 2009 Ruolo dei nuovi agenti trombopoietici nella terapia dell ITP Dr. Roberto Stasi Department of Haematology
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationClinical Policy Bulletin: Romiplostim (Nplate)
Romiplostim (Nplate) Page 1 of 8 Aetna Better Health 2000 Market Suite Ste. 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Romiplostim (Nplate) Number: 0768 Policy Aetna considers
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationClinical decision making in ITP: When to treat and how to treat
Clinical decision making in ITP: When to treat and how to treat Beng Hock Chong MBBS,PhD,FRACP, FRCPA,FRCP Professor of Medicine, University of New South Wales, Sydney and Director of Hematology, St George
More informationTavalisse (fostamatinib disodium hexahydrate)
Tavalisse (fostamatinib disodium hexahydrate) Policy Number: 5.01.661 Last Review: 07/2018 Origination: 07/2018 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationCancer Biology 2016;6(3) Immune Thrombocytopenia: Single Institute Experience. Mohammed A. Albalawi, MD
Immune Thrombocytopenia: Single Institute Experience Mohammed A. Albalawi, MD Medicine department, College of Medicine, Taibah University. Email: albalawi_21@hotmail.com Abstract: Immune thrombocytopenia
More informationASH Draft Recommendations for Immune Thrombocytopenia
ASH Draft Recommendations for Immune Thrombocytopenia INTRODUCTION American Society of Hematology (ASH) guidelines are based on a systematic review of available evidence. Through a structured process,
More informationImmune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP) ITP - What is it? ITP is a blood disorder affecting platelets in the blood. Platelets are small cells in your blood that help your blood to clot. In ITP the body s immune
More informationLupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationFor platelet control as individual as you
For platelet control as individual as you Explore the possibilities of Immune Thrombocytopenic Purpura (ITP) treatment. Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis
More informationSummary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z
Topic Page: Systemic Lupus Erythematosus Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z What Is It? Lupus is thought to develop when the immune system
More informationCase Report Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
Volume 2012, Article ID 318597, 4 pages doi:10.1155/2012/318597 Case Report Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia Maria Fernanda Gonzalez and Jonathan
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationWhen the Plate is not Full
NO DISCLOSURES DISCLOSURES When the Plate is not Full James W. Haynes, M.D. Dept of Family Medicine Univ of TN College of Medicine (Chattanooga) Thrombocytopenia Mild 70 149K / Severe < 20K > 50 often
More informationThrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13
Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists
More informationThrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary
Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit OBJECTIVE The intent of the prior authorization
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationRituximab for the treatment of Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Rituximab for the treatment of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) February 2015 2015 Summary Rituximab (MabThera,
More informationThere are two main causes of a low platelet count
Thrombocytopenia Thrombocytopenia is a condition in which a person's blood has an unusually low level of platelets Platelets, also called thrombocytes, are found in a person's blood along with red blood
More informationUse of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia
Use of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia KRISTINA WILLIAMS ABSTRACT Commercialized intravenous immunoglobulin (IVIG) products have been used
More informationAnemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi
Anemia (3).ms4.25.Oct.15 Hemolytic Anemia Abdallah Abbadi Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k, retics 12%, LDH
More informationComplement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia
THROMBOCYTOPENIA Complement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia Erin Roesch, MD, and Catherine Broome, MD Abstract Immune thrombocytopenia (ITP) is a disease process
More informationJacquelyn Zimmerman, Kelly J. Norsworthy, and Robert Brodsky. 1. Introduction
Case Reports in Hematology Volume 2016, Article ID 5403612, 4 pages http://dx.doi.org/10.1155/2016/5403612 Case Report Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory
More informationImmune Thrombocytopenia. A Practical Guide for Nurses and Other Allied Healthcare Professionals
Immune Thrombocytopenia A Practical Guide for Nurses and Other Allied Healthcare Professionals Contents Chapter 1: Overview of immune thrombocytopenia 3 Chapter 2: Identifying immune thrombocytopenia 7
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationLupus The Clinical Perspective
Lupus The Clinical Perspective Anca D. Askanase, M.D., M.P.H. Associate Professor of Medicine Director Lupus Center Columbia University Medical Center New York-Presbyterian Hospital Systemic Lupus Erythematosus
More informationWarm Autoantibodies in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report
Warm Autoantibodies in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report Emily Coberly, MD Department of Pathology and Anatomical Sciences University of Missouri Columbia April 30, 2013
More informationPromacta (eltrombopag)
Promacta (eltrombopag) Policy Number: 5.01.542 Last Review: 5/2018 Origination: 6/2013 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Promacta
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More informationACP Rheumatology Pearls. Adam Q Carlson MD Assistant Professor UVA Rheumatology
ACP Rheumatology Pearls Adam Q Carlson MD Assistant Professor UVA Rheumatology Disclosures I have no personal or professional disclosures Case #1 27 yo woman with a history of systemic lupus complicated
More information* Renal insufficiencies
Thrombotic Thrombocytopenic Purpura Behzad Poopak, DCLS PhD. Tehran medical Branch Islamic Azad university bpoopak@yahoo.com Case Summary Ms. X, a 35-year year-old woman Complained of weakness, low grade
More informationPathology note 8 BLEEDING DISORDER
Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more
More informationLearning about Lupus. Learning About Lupus. Lupus Society of Illinois
Learning About Lupus Learning about Lupus Lupus Society of Illinois 525 W. Monroe Street, Suite 900 Chicago, Illinois 60661 Robert S. Katz, M.D. Professor of Medicine Rush University Medical Center Northwestern
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationAPPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up
Supplementary Digital Content 2 Mazodier Lupus Anticoagulant- Hypoprothrombinemia Syndrome: Report of 8 Cases and Review of the Literature Medicine (Baltimore). 2012;91(5). APPEIX 2 Eight New Cases of
More informationSLE: Neuropsychiatric Lupus. Disclosures. Learning Objective 4/16/2018
SLE: Neuropsychiatric Lupus Richard Furie, MD Chief, Division of Rheumatology Northwell Health Professor of Medicine Zucker School of Medicine at Hofstra Northwell Disclosures Nothing to disclose in relationship
More informationCytopaenias in HIV. Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH
Cytopaenias in HIV Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH Introduction Cytopaenias in HIV are common Anaemias multifactorial causes Thrombocytopaenias may be the first
More informationDialogue between Clinician and Pathologist on CBC report
Dialogue between Clinician and Pathologist on CBC report Dr. Seema Bhatwadekar Haematologist, Oncohaematologist & Transplant Physician Vadodara. CBC PBS Most important test to make probable diagnosis Crucial
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationMeasuring Thrombopoietin
Measuring Thrombopoietin - 2012 A New Tool for Hematologists? Mervyn A. Sahud, M.D. A.B.I.M.-Hem. Medical Director, Coagulation Department Quest Diagnostics Nichols Institute San Juan Capistrano, CA Disclosure
More informationTo live with lupus, we need to know about lupus.
To live with lupus, we need to know about lupus. Zineb Aouhab, MD Assistant Professor of Medicine Loyola University Medical Center Division of Rheumatology 1 Where did the word lupus come from? The word
More informationDiagnosis / Lab Findings
Diagnosis / Lab Findings During at acute episode may see Peripheral smear bite cells, Heinz bodies Reticulocytosis Increased indirect bilirubin G6PD will be normal or high during an acute crisis Repeat
More informationRituximab for the treatment of adults with idiopathic (immune) thrombocytopenic purpura (ITP)
Bedfordshire and Luton Joint Prescribing Committee Date: September 2015 Review date: September 2018 Bullletin 221: Rituximab (MabThera ) for the treatment of adults with idiopathic (immune) thrombocytopenic
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationImmune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy
Rashid et al. BMC Nephrology (2018) 19:69 https://doi.org/10.1186/s12882-018-0868-7 CASE REPORT Open Access Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy
More informationThe ITP Patient Advocate
The ITP Patient Advocate A Resource for Your Journey With Chronic ITP Visit nplate.com for more information Issue Two Medical News About Nplate This issue looks at a recent 1-year Nplate medical study
More information